CA
GILD icon

Cambridge Advisors’s Gilead Sciences GILD Stock Holding History

Cambridge Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$284K Hold
2,250
– – 0.05% 160
2026
Q1 		$314K Hold
2,250
– – 0.06% 149
2025
Q4 		$276K Hold
2,250
– – 0.05% 158
2025
Q3 		$250K Sell
2,250
-200
-8% -$22.7K 0.05% 162
2025
Q2 		$272K Hold
2,450
– – 0.06% 153
2025
Q1 		$275K Hold
2,450
– – 0.06% 151
2024
Q4 		$226K Sell
2,450
-200
-8% -$18K 0.05% 161
2024
Q3 		$222K Buy
+2,650
New +$202K 0.05% 163
2024
Q1 		– Sell
-2,650
Closed -$215K – 169
2023
Q4 		$215K Sell
2,650
-440
-14% -$34.2K 0.05% 159
2023
Q3 		$232K Hold
3,090
– – 0.06% 153
2023
Q2 		$238K Hold
3,090
– – 0.06% 153
2023
Q1 		$256K Hold
3,090
– – 0.07% 162
2022
Q4 		$265K Sell
3,090
-7,400
-71% -$586K 0.07% 152
2022
Q3 		$647K Buy
10,490
+100
+1% +$6.31K 0.19% 93
2022
Q2 		$642K Sell
10,390
-200
-2% -$12.4K 0.18% 93
2022
Q1 		$630K Sell
10,590
-560
-5% -$35.8K 0.15% 106
2021
Q4 		$810K Sell
11,150
-200
-2% -$13.8K 0.18% 88
2021
Q3 		$793K Hold
11,350
– – 0.19% 84
2021
Q2 		$782K Sell
11,350
-320
-3% -$21.4K 0.19% 86
2021
Q1 		$754K Buy
11,670
+2,500
+27% +$161K 0.19% 83
2020
Q4 		$534K Sell
9,170
-218
-2% -$13.2K 0.14% 94
2020
Q3 		$593K Sell
9,388
-160
-2% -$11.1K 0.17% 86
2020
Q2 		$735K Buy
9,548
+775
+9% +$59.4K 0.23% 71
2020
Q1 		$656K Buy
8,773
+1,359
+18% +$93.9K 0.24% 73
2019
Q4 		$482K Sell
7,414
-50
-0.7% -$3.26K 0.15% 95
2019
Q3 		$473K Sell
7,464
-300
-4% -$19.6K 0.16% 84
2019
Q2 		$525K Sell
7,764
-750
-9% -$49.3K 0.17% 87
2019
Q1 		$553K Sell
8,514
-50
-0.6% -$3.32K 0.19% 86
2018
Q4 		$536K Sell
8,564
-1,050
-11% -$73.4K 0.2% 82
2018
Q3 		$742K Sell
9,614
-300
-3% -$22.7K 0.25% 76
2018
Q2 		$702K Sell
9,914
-150
-1% -$10.6K 0.25% 75
2018
Q1 		$759K Buy
10,064
+3,200
+47% +$254K 0.27% 67
2017
Q4 		$492K Sell
6,864
-30
-0.4% -$2.28K 0.18% 88
2017
Q3 		$559K Hold
6,894
– – 0.21% 76
2017
Q2 		$488K Sell
6,894
-390
-5% -$26K 0.2% 87
2017
Q1 		$495K Sell
7,284
-150
-2% -$10.5K 0.2% 84
2016
Q4 		$532K Sell
7,434
-955
-11% -$71K 0.24% 75
2016
Q3 		$664K Sell
8,389
-350
-4% -$28.4K 0.29% 69
2016
Q2 		$729K Sell
8,739
-270
-3% -$24K 0.33% 61
2016
Q1 		$828K Buy
9,009
+150
+2% +$13.5K 0.38% 57
2015
Q4 		$896K Buy
8,859
+754
+9% +$78.5K 0.51% 50
2015
Q3 		$796K Buy
8,105
+50
+0.6% +$5.55K 0.47% 55
2015
Q2 		$943K Buy
8,055
+805
+11% +$88K 0.53% 50
2015
Q1 		$1.16M Sell
7,250
-1,305
-15% -$133K 0.68% 37
2014
Q4 		$806K Buy
+8,555
New +$885K 0.49% 57

Other funds holding GILD

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
CIM
Confluence Investment Management St. Louis, Missouri $6.4B AUM 9.79% 1-Year Est. Return
ATO
Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return
CGH
Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return

Cambridge Advisors's GILD Position: Q2 2026 in Review

Cambridge Advisors held its Gilead Sciences (GILD) position steady in Q2 2026 at 2,250 shares worth $284K. The position accounts for 0.05% of the portfolio, ranked #160.

Cambridge Advisors first reported a position in GILD in Q4 2014 and has held it in 45 quarters since. The position peaked at $1.16M in Q1 2015. 690 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Cambridge Advisors held 2,250 shares of Gilead Sciences worth $284K as of Q2 2026.
  • Cambridge Advisors left its Gilead Sciences share count unchanged in Q2 2026.
  • Gilead Sciences made up 0.05% of Cambridge Advisors's portfolio in Q2 2026, its #160 holding.
  • Cambridge Advisors first reported a position in Gilead Sciences in Q4 2014 and has held it in 45 quarters since.
  • Cambridge Advisors's Gilead Sciences position peaked at $1.16M in Q1 2015.
  • 690 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Cambridge Advisors's 13F filing for Q2 2026, filed 16 Jul 2026.